Abstract:
Provided is a method for producing mesenchymal stem cells from human pluripotent stem cells, the method including: a) forming embryonic bodies from human pluripotent stem cells; b) attaching the embryonic bodies to a culture dish to induce natural differentiation of the embryonic bodies into mesenchymal stem cells; and c) performing continuous proliferative culturing of the mesenchymal stem cells while still maintaining the identity of the mesenchymal stem cells. Also, provided is a standardized method for inducing differentiation of mesenchymal stem cells, which can be broadly applied to all human pluripotent stem cells regardless of a difference in the genetic background thereof. Ultimately, the present invention can continuously mass-produces the mesenchymal stem cells necessary for regenerative medicine and cell therapy by using human pluripotent stem cells, thereby realizing practical uses of cell therapy products, and further the present invention is expected to highly contribute to treatments of incurable diseases, such as cardiovascular diseases and neurological disorders.
Abstract:
The present invention relates to a method for mass-producing angiogenesis factors using stem cell aggregates and a composition for treating and preventing ischemic diseases including culture medium of the stem cell aggregates. More specifically, in the present invention, stem cell aggregates are made in a buffer solution, which has less stability and less fetal bovine serum derived from animals and a non-additive basal medium, which has no antibiotics to increase tolerance via a suspension culture, thereby mass-producing angiogenesis factors from the stem cell aggregate culture medium while the survival rate of the angiogenesis factor remarkably increases, when transplanted to ischemic tissues, compared with that of transplanted single cells, so the composition of the present invention can be used for efficiently treating or preventing ischemic diseases.
Abstract:
The present invention provides a pharmaceutical composition for treating ischemic diseases containing human blood derived hematosphere. Specifically the present invention induces vascular smooth muscle cells and vascular endothelial cells through effective three-dimensional culture using mononuclear cells of blood, and ultimately can be applied for the development of a new cell treatment agent for treating the ischemic diseases through effective angiogenesis.
Abstract:
The present invention relates to a technology in which only trace amounts of adult stem cells and progenitor cells present in the blood are effectively cultured and proliferated by using blood mononuclear cells, thereby differentiating inflammatory mononuclear cells into anti-inflammatory mononuclear cells and efficiently securing masses of anti-inflammatory Type 2 helper lymphocytes and regulatory lymphocytes, and a method for treating immune-related diseases using the technology. The anti-inflammatory mononuclear cells, Type 2 helper lymphocytes, and regulatory lymphocytes according to the present invention are immune cells derived from patients, and thus can greatly contribute to the development of cell therapeutic agents for autoimmune diseases.
Abstract:
PURPOSE: A pharmaceutical composition for treatment of metabolic diseases including a blood-born hemosphere (BBHS) is provided to be able to be used as medicine for metabolic diseases by inducing differentiation of BBHS to an insulin-secreting cell. CONSTITUTION: A pharmaceutical composition for treatment of metabolic diseases includes BBHS. The BBHS is formed by isolating monocytic cells from human blood and performing the three dimensional aggregation cultivation. The BBHS is induced to an insulin-secreting cell. The metabolic diseases are selected from a group consisting of diabetes, hyperlipidemia, and obesity. A method of curing metabolic diseases administers the pharmaceutically effective dose of the pharmaceutical composition to an individual.
Abstract:
PURPOSE: A method for inducing and culturing cardiac stem cells using cell aggregation is provided to extract obtain a large amount of stem cells. CONSTITUTION: A method for inducing and culturing cardiac stem cells using cell aggregation comprises: a step of isolating differentiation cells from heart; a step of culturing cells in a three-dimensional structure; a step of proliferating cells and culturing organ; and a step of culturing and storing for a long time and thawing again to obtain secondary cardiac sphere.